Gilead Sciences [GILD] has a 3.5% dividend yield, with underlying growth coming from its core franchise in HIV and, potentially, remdesivir, a drug that could be used to treat Covid-19.Management continues to drive top-line growth through investment in research and development, which leads to new-product innovation and improved pricing, and accretive acquisitions.